Tribe Clinical Research (TCR) in Greenville, South Carolina, has announced the commencement of a Phase 3 clinical trial investigating a new drug for the prevention of Alzheimer's disease. This trial represents a significant step forward in the ongoing efforts to combat this debilitating condition, which affects millions worldwide.
The Phase 3 trial, expected to last five years, will assess the efficacy and safety of an injectable drug designed to prevent or slow the progression of Alzheimer's. According to TCR's CEO, Jenn Lehman, the drug is anticipated to cause fewer side effects than current treatments, potentially offering a better quality of life for patients. The trial is enrolling participants between the ages of 65 and 80.
Trial Design and Objectives
The study involves a free pre-screening process to identify individuals with biomarkers indicating a predisposition to developing Alzheimer's. This proactive approach allows for early intervention, which is crucial in managing the disease. Enrolled participants will receive specialized healthcare throughout the trial's duration, with the aim of preventing or slowing the advancement of Alzheimer's. Participants will also be compensated for their time and travel expenses.
Current Alzheimer's Treatment Landscape
Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. Current treatments primarily focus on managing symptoms rather than preventing or curing the disease. The development of new therapies that can effectively prevent or slow the progression of Alzheimer's is a critical unmet medical need.
Participant Information
TCR is offering free pre-screenings at its Greenville and Spartanburg locations. Individuals interested in participating can schedule an appointment to determine their eligibility. The trial aims to provide not only potential therapeutic benefits but also comprehensive healthcare and compensation for participants' involvement.
